Pharmacyte Biotech Inc (OTCMKTS:PMCB) announced that its diabetes treatment and the research plan of its international Diabetes Consortium was showcased at the Austrodrugs 2015 conference held on June 12 in Austria. It is one of the famous and renowned disease treatment development conferences in central Europe. The prestigious Austrodrugs conference is organized by the CeMM in Austria. It is the international, interdisciplinary and independent research unit of the Austrian Academy of Sciences.
Dr. Eva-Maria Brandtner, the Director of Pharmacyte’s Diabetes Program Development, was invited to speak at the conference. She highlighted role of encapsulated Insulin-producing Cells to cure diabetes during the presentation. Dr. Brandtner is currently Head of the Bio-encapsulation Unit at the VIVIT in Austria. Before joining the VIVIT team, she was with Austrianova Singapore where she headed the initial trials with Melligen insulin-producing cells, both encapsulated and non-encapsulated, utilizing the Cell-in-a-Box® live-cell encapsulation technology.
Melligen cells, which were developed by Professor Dr. Ann Simpson and her colleagues from a human liver cell line, have been demonstrated to be able to release insulin as the level of blood sugar increases in their surroundings. During the presentation, she highlighted the Diabetes Consortium’s ongoing trials with Melligen cells.
Pharmacyte Biotech’s CEO, Kenneth L. Waggoner, said that the management is very delighted that Dr. Brandtner was invited to deliver important presentation at the renowned Austrodrugs conference in Vienna. He added that because of her prior experience with Melligen cells and her existing role in company’s international Diabetes Consortium, Dr. Brandtner was the ideal choice to deliver this presentation. The presentation will offer visibility to international Diabetes Consortium’s initiatives to formulate a treatment for insulin-supported diabetes.
In last trading session, the stock price of Pharmacyte Biotech Inc (OTCMKTS:PMCB) declined more than 3% to close the trading session at $0.133. The decline came at a share volume of 1.27 million compared to average share volume of 1.92 million.